

The Innovation Drug Discovery: An international journal of drug discovery science

Jun Lu,^{1,*} Jean-Marie Lehn,² Albert Sun Chi Chan,³ and Shilin Chen¹

¹Institute of Herbgenomics, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China

²ISIS - Université de Strasbourg, 8 allée Gaspard Monge, F-67000 Strasbourg, France

³School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China

*Correspondence: ljaa111@163.com

Received: ; Accepted: March 2, 2026; Published Online: April 2, 2026; <https://doi.org/10.59717/j.xinn-drugdisc.2026.100001>

© 2026 The Author(s). This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>).

Citation: Lu J., Lehn J., Sun A., et al. (2026). The Innovation Drug Discovery: An international journal of drug discovery science. *The Innovation Drug Discovery* 1:100001.

Since the dawn of human civilization, we have never halted our struggle against disease nor our pursuit of health. Drug discovery, as a pivotal domain within the life sciences, embodies humanity's profound understanding of fundamental life processes and its relentless pursuit of curing diseases.

Historically, drug discovery long relied on empirical knowledge and serendipity. However, with the rise of modern science—particularly breakthroughs in molecular biology, structural biology, genomics, and related fields—the discipline has progressively transitioned from being “experience-driven” to “science-driven.” Microscopes unveiled the cellular world, X-ray diffraction revealed the DNA double helix, high-throughput sequencing unlocked the genome, and artificial intelligence alongside big data are now reshaping the paradigm of drug research and development. We have moved from “understanding disease” to “designing drugs,” from targeting “single molecules” to modulating “systemic networks,” and from small chemical entities to biologics, cell therapies, and gene-based treatments.

Innovation is both the perennial theme and the foremost challenge in drug discovery. Today, the spectrum of diseases grows increasingly complex: emerging and re-emerging infectious threats loom globally, while cancer, neurodegenerative disorders, metabolic diseases, and others remain inadequately conquered. Concurrently, interdisciplinary convergence is catalyzing a new generation of drug discovery paradigms. Computational chemistry and artificial intelligence accelerate candidate screening; structural biology and

cryo-electron microscopy elucidate mechanisms of drug action; synthetic biology and gene-editing technologies pioneer novel therapeutic pathways; and materials science and nanotechnology revolutionize drug delivery. Drug discovery is no longer merely a dialogue between chemistry and biology, but rather a symphony integrating mathematics, physics, informatics, engineering, ethics, and social sciences.

Against this backdrop, we launch **The Innovation Drug Discovery**, an international scholarly journal dedicated to establishing a high-caliber platform for disseminating frontier research, fostering interdisciplinary collaboration, and advancing transformative paradigms. **The Innovation Drug Discovery** commits to publishing original, rigorous, and forward-thinking research that spans the entire spectrum of drug innovation—from target identification and validation, lead discovery and optimization, and preclinical studies to translational medicine and emerging therapeutic strategies. We particularly encourage interdisciplinary investigations encompassing, but not limited to, computational drug design, AI-aided development, novel delivery systems, drug repurposing, personalized medicine, and digital health.

The Innovation Drug Discovery will uphold the principles of openness, collaboration, rigor, and innovation. Our internationally diverse editorial team will implement a transparent and equitable peer-review process, serving the global scientific community. We envision this journal as a fertile ground for inspiring creativity, exchanging ideas, and nurturing partnerships.

